[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Merck & Company (MRK)

Merck & Company (MRK)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Market News and Commentary

Wolfe Research Just Upgraded Moderna Stock. Here's Why.

Moderna (MRNA) shares extended gains on Aug. 25 after Wolfe Research upgraded the biotech giant, citing recent positive developments surrounding its personalized cancer vaccine. 

Analyst Alexandria Hammond now rates MRNA at “Peer Perform,” albeit without a particular price target that explains how high the stock could fly in the second half of 2026. 

Fundamentals

See More
  • Market Capitalization, $K 371,704,160
  • Shares Outstanding, K 2,467,172
  • Annual Sales, $ 65,011 M
  • Annual Income, $ 18,254 M
  • EBIT $ 6,984 M
  • EBITDA $ 12,822 M
  • 60-Month Beta 0.19
  • Price/Sales 5.79
  • Price/Cash Flow 13.35
  • Price/Book 8.97

Options Overview Details

View History
  • Implied Volatility 30.03% (+0.98%)
  • Historical Volatility 39.99%
  • IV Percentile 57%
  • IV Rank 60.85%
  • IV High 35.42% on 04/27/26
  • IV Low 21.66% on 12/08/25
  • Expected Move (DTE 3) 3.60 (2.30%)
  • Put/Call Vol Ratio 0.27
  • Today's Volume 48,705
  • Volume Avg (30-Day) 35,444
  • Put/Call OI Ratio 0.71
  • Today's Open Interest 549,614
  • Open Int (30-Day) 471,692
  • Expected Range 152.85 to 160.05

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 28 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/26
See More
  • Average Estimate $2.27
  • Number of Estimates 5
  • High Estimate $2.41
  • Low Estimate $2.20
  • Prior Year $2.58
  • Growth Rate Est. (year over year) -12.02%

Price Performance

See More
Period Period Low Period High Performance
1-Month
126.22 +23.95%
on 08/04/26
156.92 -0.30%
on 08/25/26
+25.38 (+19.36%)
since 07/24/26
3-Month
111.57 +40.23%
on 06/18/26
156.92 -0.30%
on 08/25/26
+34.04 (+27.81%)
since 05/22/26
52-Week
77.58 +101.66%
on 09/25/25
156.92 -0.30%
on 08/25/26
+71.14 (+83.39%)
since 08/25/25

Most Recent Stories

More News
Wolfe Research Just Upgraded Moderna Stock. Here's Why.

Moderna stock rallies as Wolfe Research upgrades it to "Peer Perform." But is there any further upside left in MRNA shares? Let’s find out!

MRK : 156.45 (+3.84%)
MRNA : 158.83 (+14.36%)
BioNTech Moved Higher as the Broader Biotech Sector Hit a Post-Pandemic Peak, but BNTX Stock Needs Stronger Fundamentals to Keep Climbing

BioNTech shares moved higher as the broader biotech sector reached a post-pandemic peak, lifted by positive late-stage cancer vaccine data from peers rather than new clinical results of its own.

MRK : 156.45 (+3.84%)
IBB : 216.40 (+1.82%)
MRNA : 158.83 (+14.36%)
XBI : 169.10 (+3.00%)
PFE : 28.57 (+2.15%)
BNTX : 114.05 (+1.09%)
BMY : 67.92 (+0.95%)
2 Biotech Stocks Shaping Up for Major Breakouts

Moderna's mRNA cancer vaccine breakthrough with Merck fueled a biotech rally, with the IBB near highs. Eli Lilly and Natera both show strong uptrends and possible breakouts.

NTRA : 336.71 (+2.74%)
MRK : 156.45 (+3.84%)
IBB : 216.40 (+1.82%)
LLY : 1,233.66 (-1.06%)
MRNA : 158.83 (+14.36%)
MarketBeat Week in Review – 08/17 - 08/21

Stocks fell this week as Treasury bond buybacks, oil prices, and Walmart earnings weighed on markets, while Bitcoin rallied; MarketBeat analysts cover Moderna, NVIDIA, Meta, RTX, and more.

BDC : 116.96 (+0.17%)
NVDA : 213.05 (+2.19%)
GOOGL : 346.96 (-0.32%)
META : 570.05 (+1.97%)
AMAT : 480.04 (-0.86%)
BE : 217.45 (+6.58%)
MRK : 156.45 (+3.84%)
TMC : 4.96 (+4.75%)
OKTA : 130.61 (-0.27%)
SQM : 79.21 (-3.79%)
SKHY : 159.53 (+2.68%)
OSW : 26.26 (-0.94%)
Stocks Settle Higher as Crude Oil Prices Stabilize

The S&P 500 Index ($SPX ) (SPY ) closed up by +0.43% on Friday, the Dow Jones Industrial Average ($DOWI ) (DIA ) closed up by +0.98%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) closed up by +0.33%. E-mini...

MSTR : 126.83 (+3.42%)
TER : 366.43 (+0.42%)
AMAT : 480.04 (-0.86%)
B : 48.87 (+1.47%)
CNP : 38.93 (-0.43%)
SRE : 84.03 (-0.64%)
MRK : 156.45 (+3.84%)
$IUXX : 29,209.23 (+0.64%)
COIN : 187.16 (+4.28%)
ZNU26 : 108-280 (+0.01%)
TSLA : 350.25 (+0.37%)
ESU26 : 7,673.75 (-0.24%)
Moderna Just Doubled on a Massive Cancer Breakthrough. Here’s Why MRNA Stock Isn’t a Buy Yet.

Moderna's cancer treatment could treat more than just Melanoma, though the stock's momentum is already stalling. Should you still buy the dip?

MRK : 156.45 (+3.84%)
MRNA : 158.83 (+14.36%)
NVAX Stock Alert: Biotechs Hit Post-Pandemic High on mRNA Cancer Breakthrough

NVAX stock surges amid biotech stock rally following Moderna and Merck cancer breakthrough.

$NASX : 26,151.30 (+0.66%)
MRK : 156.45 (+3.84%)
NVAX : 9.44 (+6.55%)
MRNA : 158.83 (+14.36%)
XBI : 169.10 (+3.00%)
SNY : 46.02 (+0.72%)
BNTX : 114.05 (+1.09%)
Stocks Supported as Crude Oil Stabilizes

The S&P 500 Index ($SPX ) (SPY ) is up by +0.38% today, the Dow Jones Industrial Average ($DOWI ) (DIA ) is up by +0.69%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) is up by +0.09%. E-mini S&P futures (ESU26...

MSTR : 126.83 (+3.42%)
TER : 366.43 (+0.42%)
AMAT : 480.04 (-0.86%)
B : 48.87 (+1.47%)
GLXY : 24.79 (+8.54%)
MRK : 156.45 (+3.84%)
$IUXX : 29,209.23 (+0.64%)
COIN : 187.16 (+4.28%)
ZNU26 : 108-280 (+0.01%)
ESU26 : 7,673.75 (-0.24%)
STX : 821.67 (+3.40%)
WDC : 450.75 (+3.53%)
Moderna’s 177% Surge Has Investors Asking What Comes Next

Moderna shares surged 177% after its melanoma vaccine, developed with Merck, outperformed an established therapy in a late-stage trial, triggering a massive short squeeze.

MRK : 156.45 (+3.84%)
MRNA : 158.83 (+14.36%)
Trump’s Moderna Trade Up Over 200% After Historic mRNA Cancer Vaccine Trial

Shares of Moderna ($MRNA) closed up nearly 177% at $174.38 on August 19 after the company and Merck ($MRK) announced positive Phase 3 results for their personalized mRNA cancer therapy, pushing Moderna's...

MRK : 156.45 (+3.84%)
MRNA : 158.83 (+14.36%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Buy with a Strongest short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

Relative Strength is above 70%. The market is in overbought territory. Watch for a potential trend reversal.

See More Share

Business Summary

Merck & Co. boasts more than six blockbuster drugs in its portfolio with PD-L1 inhibitor, Keytruda, approved for several types of cancer. Keytruda has played an instrumental role in driving Merck's steady revenue growth in the past few years. Well-known products in Merck's portfolio include Keytruda,...

See More

Key Turning Points

3rd Resistance Point 164.95
2nd Resistance Point 160.94
1st Resistance Point 158.69
Last Price 156.45
1st Support Level 152.43
2nd Support Level 148.42
3rd Support Level 146.17

See More

52-Week High 156.92
Last Price 156.45
Fibonacci 61.8% 126.61
Fibonacci 50% 117.25
Fibonacci 38.2% 107.89
52-Week Low 77.58

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.